首页> 外文期刊>International Journal of Research in Medical Sciences >Study of reactivity pattern of hormone receptors in patients with breast cancer at a tertiary care hospital, Aurangabad, India
【24h】

Study of reactivity pattern of hormone receptors in patients with breast cancer at a tertiary care hospital, Aurangabad, India

机译:印度奥兰加巴德一家三级医院的乳腺癌患者激素受体的反应模式研究

获取原文
       

摘要

Background: Breast cancer is one of the most common malignancies affecting the female population worldwide. Prognosis and management of breast cancer are influenced by variables such as stage, grade, and hormone receptor status. Tumours that express ER and/or PR have a better prognosis and most of them respond well to hormonal therapy. In addition to hormone receptors, HER2 has emerged in recent years as an important independent predictive marker. Methods: All surgically operated female cases of breast carcinoma which were submitted for immunohistochemistry test for estrogen, progesterone and human epidermal growth factor receptor-2 in the Department of Pathology, MGM Medical College, Aurangabad for the duration of December 2015 to October 2017 were included in this prospective study. A total of 50 patients were taken up for the study. Results: The maximum age of the patients were in the 4th -5th decade and were mostly premenopausal. The tumour was maximum involving the right breast, upper outer quadrant and were BI-RADS 4. Majority were grade 2 and were invasive ductal carcinoma. Hormone receptor status showed ER positivity 48%, PR positivity 46% and HER2 positivity 28%. Conclusions: So, to conclude, immunohistochemical analysis of ER, PR and HER2 receptors is widely available at a reasonable cost and provides valuable prognostic, predictive and therapeutic information. Although we could see different patterns of hormonal receptor status, irrespective of the histological grade, type and lymph node status in our study, HER2 testing along with ER/PR status should be performed routinely in all the patients diagnosed of breast cancer as this will help the clinicians to manage the patients further.
机译:背景:乳腺癌是影响全球女性人口的最常见的恶性肿瘤之一。乳腺癌的预后和管理受到阶段,等级和激素受体状态等变量的影响。表达ER和/或PR的肿瘤预后较好,并且大多数对激素治疗反应良好。除激素受体外,HER2近年来已作为重要的独立预测标记物出现。方法:纳入2015年12月至2017年10月在奥兰加巴德米高梅医学院病理学部接受免疫组织化学法检测雌激素,孕激素和人表皮生长因子受体2的所有乳腺癌手术女性病例。在这项前瞻性研究中。共有50名患者被纳入研究。结果:患者的最大年龄在第4-5世纪,大部分是绝经前。肿瘤最大,累及右乳,上象限,为BI-RADS4。多数为2级,为浸润性导管癌。激素受体状态显示ER阳性48%,PR阳性46%,HER2阳性28%。结论:因此,总而言之,可以以合理的成本广泛获得ER,PR和HER2受体的免疫组织化学分析,并提供有价值的预后,预测和治疗信息。尽管我们可以观察到激素受体状态的不同模式,但无论我们的研究中的组织学等级,类型和淋巴结状态如何,所有诊断为乳腺癌的患者均应常规进行HER2检测以及ER / PR状态临床医生进一步管理患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号